Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| AstraZeneca PLC | IMFINZI (Durvalumab) + LYNPARZA (olaparib) - (BAYOU) | Stage IV urothelial carcinoma (UC) | Phase 2 | Trial Completed | Intravenous and oral | Oncology |
| AstraZeneca PLC | Evusheld (AZD7442) - (PROVENT) | COVID-19 | Phase 3 | Withdrawn | Intramuscular | COVID-19 |
| AstraZeneca PLC | FASENRA (benralizumab) - (MESSINA) | Eosinophilic Esophagitis | Phase 3 | Data Released | Subcutaneous | Gastroenterology |
| AstraZeneca PLC | FASENRA (benralizumab) - (NATRON) | Hyper-eosinophilic syndrome (HES) | Phase 3 | Data Released | Subcutaneous | Immunology |
| AstraZeneca PLC | IMFINZI (durvalumab) - (CALLA) | Cervical cancer | Phase 3 | Trial Discontinued | Intravenous | Oncology |
| AstraZeneca PLC | FARXIGA (Dapagliflozin) | COVID-19 | Phase 3 | Trial Discontinued | Oral | COVID-19 |
| AstraZeneca PLC | AZD7442 (STORMCHASER) | COVID-19 (post-exposure prophylaxis) | Phase 3 | Trial Discontinued | Intramuscular | COVID-19 |
| AstraZeneca PLC | ENHERTU - (DESTINY-Gastric04) | Gastric or gastroesophageal junction (GEJ) adenocarcinoma | Phase 3 | Data Released | Intravenous | Oncology |
